Drug intelligence / Profile preview

KBD991

Development stage: Preclinical
Lead developer: Kangbaida
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

KBD991 is a preclinical-stage radiopharmaceutical candidate being developed by Kangbaida, a subsidiary of Chengdu Baiyu Jingelai Pharmaceutical, for the treatment of oncology indications. The specific biological target and mechanism of action of KBD991 remain undisclosed.

Beyond the preview

Go deeper on KBD991.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KBD991.

Explore the full profile